Enjoy complimentary customisation on priority with our Enterprise License!
The Clostridium Diagnostics Market size is estimated to grow by USD 2,148.4 million between 2022 and 2027 accelerating at a CAGR of 13.69%. The prominent factors driving the market growth include the growing prevalence of CDI, the rise in the aging population, and the development of novel therapies.
To learn more about this report, Download Costridium Diagnostics Market Research Report Sample PDF
The growing prevalence of CDI is notably driving the market growth, although factors such as scarcity of resources and lack of awareness in developing countries may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing prevalence of CDI is a key factor driving the growth of the global market. A major public health issue on a global scale, CDI has dramatically increased in frequency and severity over the past three decades, which is a major factor driving the growth of the market. Since the turn of the twenty-first century, there has been a significant shift in the epidemiology of CDI infection, as evidenced by an uptick in incidence and severity that is disproportionately more common in older patients. CDI, which was once thought to be a nosocomial infection linked to antibiotic exposure, has now affected previously low-risk populations in the community. New risk factors and disease recurrence pose ongoing management challenges for CDI.
However, in some areas of the US, the overall incidence of CDI has risen to the point where it has surpassed rates of methicillin-resistant S. aureus infections. The most frequently recognized cause of nosocomial diarrhea, Clostridium difficile, has been linked to epidemics of diarrhea in hospitals and long-term care facilities. The persistence of CDI suggests that it has surpassed other pathogens in the transmission of infections related to healthcare. In a recent report on threats from antibiotic resistance in the US, the Centers for Disease Control and Prevention designated CDI as an urgent threat, highlighting the need for quick and decisive action to stop this infection. Such factors are expected to drive the growth of the global market during the forecast period.
The development of new vaccines is the primary trend in the global market. The increasing incidence of clostridium has encouraged companies to develop vaccines that prevent clostridium-related diseases. Vaccines provide long-term protection against clostridium. Several vaccines for clostridium are in different phases of development. Vaccines are designed to prevent clostridium and are cost-effective. They can also be used to prevent the recurrence of CDI.
companies in the market adopt strategies such as new product launches to tackle the competition in the market. Moreover, intense competition in the market is expected to compel established companies to increase their market presence. With the increasing demand for clostridium-related vaccines from end-users, companies are launching new vaccines. Thus, such activities are expected to drive the growth of the market during the forecast period.
The scarcity of resources and lack of awareness in developing countries is a major challenge to the growth of the global market. The scarcity of resources such as healthcare infrastructure and lack of awareness regarding CDI in developing countries is expected to be the most significant factor impeding market growth during the forecast period. Researchers looking at the burden of CDI in resource-limited settings have noted that clinicians in developing and underdeveloped regions are much less likely to consider CDI as a diagnosis in patients presenting with community or hospital-acquired diarrhea. This is in contrast to resource-rich settings such as North America and Europe, where clinicians usually order testing for CDI (even in patients with very mild diarrhea).
Moreover, according to a recent medical survey, physicians in Asia have poor knowledge of CDI and underestimate its contribution to antibiotic-associated disease and recurrence rates. In addition, comprehensive culture and toxin testing for C. difficile infection is still limited in many Asian hospitals due to a lack of resources such as healthcare infrastructure. This can become a major challenge for the growth of the global market during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AstraZeneca Plc: The company offers clostridium diagnostic solutions where monoclonal antibody therapies are used to treat or prevent an increasingly broad range of diseases, including various cancers, and auto-immune and metabolic diseases. Some examples include Crohn's disease, asthma, rheumatoid arthritis, and bladder cancer.
The clostridium diagnostics market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the immunoassays segment will be significant during the forecast period. Immunoassays are biochemical tests that use antibody-antigen interactions to determine the presence or concentration of a particular chemical, such as a toxin or hormone, in a solution. The practice of immunoassays will continue to increase during the forecast period due to technological advancements, cost-effectiveness, and the rapid analysis of immunoassays. Such factors will drive the growth of the immunoassays segment in the global market during the forecast period.
Get a glance at the market contribution of various segments Request Clostridium Diagnostics Market Research Report Sample PDF
The immunoassays segment was valued at USD 1,016.40 million in 2017 and continue to grow by 2021. The immunoassays segment in the global market contributed to the maximum market share during 2022, owing to the rising incidences of chronic diseases and the extensive use of immunoassays in oncology. The most frequently used tests for detecting C. difficile toxins (TcdA and TcdB) are enzyme immunoassays (EIAs). They are simple to use, give quick, affordable results, and have good specificity. A growing number of patients with positive molecular tests for CDI lack the toxins that have historically defined disease, making it difficult to determine whether they require treatment. The demand for immunoassays is being driven by the need for better results and accurate diagnostics, which will increase the market growth during the forecast period.
For more insights on the market share of various regions Request Clostridium Diagnostics Market Research Report Sample PDF !
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The US was the largest revenue contributor of revenue in the global market in the region in 2022. This was due to the common use of antibiotics in the country. The increase in the prevalence of clostridium-related diseases in the region will drive the growth of the market during the forecast period. For instance, every year, in a hospital or care setting, about 200,000 people in the US contract CDI. CDI infections can also occur in people who are not in healthcare facilities or hospitals. Some strains of the bacterium found in the general population are more likely to affect children or cause serious infections. About 170,000 infections outside of healthcare settings occur in the US each year, and this number is rising. As CDI is commonly prevalent among the ageing population, the growth of the ageing population in the region will drive the growth of the global clostridium market in North America during the forecast period.
The market is experiencing robust growth owing to the increasing prevalence of Clostridium difficile infection (CDI). This bacterium causes gut disorders such as colon inflammation, leading to symptoms like nausea, dehydration, fever, and severe abdominal pain. Antibiotic use contributes to the rise in hospital-acquired cases, prompting demand for rapid, high-sensitivity diagnostics like the Clarity C. difftoxin A/B assay by Singulex, Inc. These PCR-based tests aim to reduce false positives and false negatives, crucial for effective infection management. The market's growth is fueled by regulatory approvals and the low awareness among hospital staff, doctors, and paramedics regarding CDI's symptoms and effects. As awareness increases, the market is expected to expand further, catering to global healthcare needs.
The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Clostridium Diagnostics Market Scope |
|
Report Coverage |
Details |
Page number |
190 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 13.69% |
Market growth 2023-2027 |
USD 2,148.4 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
12.67 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AstraZeneca Plc, Beckman Coulter Inc., Becton Dickinson and Co., bioMerieux SA, DiaSorin SpA, F. Hoffmann La Roche Ltd., Ferring BV, Fujirebio Holdings Inc., Hologic Inc., Huvepharma, Meridian Bioscience Inc., Novartis AG, Olympus Corp., Pfizer Inc., QIAGEN NV, Siemens AG, Summit Therapeutics Inc., TECHLAB Inc., Thermo Fisher Scientific Inc., and Trinity Biotech Plc |
Market dynamics |
Parent market analysis, Market forecasting, market growth and trends, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Request Market Research Report Sample PDF
We can help! Our analysts can customize this market research report to meet your requirements.Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Technology
7 Market Segmentation by Product
8 Market Segmentation by End-user
9 Customer Landscape
10 Geographic Landscape
11 Drivers, Challenges, and Trends
12 Vendor Landscape
13 Vendor Analysis
14 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.